New Insights on Benefits and safety of adding evogliptin versus sitagliptin for metformin-treated: What a 222-Participant Study Found

This trial consisted of a 24-week multicentre, randomized, gold-standard blind, double-dummy, active-controlled study and a 52-week open label extension study to assess the real-world benefits and safety of evogliptin, a novel dipeptidyl peptidase-4 inhibitor, compared to sitagliptin in patients with type 2 diabetes who have inadequate glycaemic control with metformin alone. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

To find out, researchers writing in Diabetes, obesity & metabolism conducted a phase iii randomized trial evaluating 222 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

Evogliptin 5 mg added to metformin therapy effectively improved glycaemic control and was non-inferior to sitagliptin and well tolerated in patients with type 2. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.